Strategic alliance combines resources to develop treatment option for dry eye syndrome
May 18, 2022
BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).